[1] Listed N. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7-29, 2000:highlights of the conference[J]. South Med J, 2001, 94(6):569-573.
[2] Lewiecki EM. New targets for intervention in the treatment of postmenopausal osteoporosis[J]. Nat Rev Rheumatol, 2011, 7(11):631-638.
[3] Riggs BL, Melton LJ Ⅲ. The worldwide problem of osteoporosis:insights afforded by epidemiology[J]. Bone, 1995, 17(5Suppl):505S-511S.
[4] Kanis JA On behalf of the World Health Organization Scientific Group. Assessment of Osteoporosis at the Primary Health-care Level[M].UK:University of Sheffield, 2008.
[5] Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe[J]. Osteoporosis Int, 2005, 16(3):229-238.
[6] Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States,2005-2025[J]. J Bone Miner Res,2007, 22(3):465-475.
[7] Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's guide to prevention and treatment of osteoporosis[J]. Osteoporos Int, 2014, 25(10):2359-2381.
[8] Rivadeneira F, Mäkitie O. Osteoporosis and bone mass disorders:from gene pathways to treatments[J]. Trends Endocrinol Metab, 2016, 27(5):262-281.
[9] Seeman E, Delmas PD. Bone quality-the material and structural basis of bone strength and fragility[J]. New Engl J Med, 2008, 26(1):1-8.
[10] Mafi Golchin M, Heidari L, Ghaderian SM, et al. Osteoporosis:a silent disease with complex genetic contribution[J]. Yi chuan xue bao, 2016, 43(2):49-61.
[11] Szabo CM, Martin MB, Oldfield E. An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs[J]. J Med Chem, 2002, 45(14):2894-2903.
[12] Lazar A, Pacurar M, Campian RS. Bisphosphonates in bone diseases treatment[J]. Rev Chimie -Bucharest, 2017, 68(2):246-249.
[13] Stute P, Birkhäuser M. Selektive Östrogenrezep-tormodulatoren (SERM)[J]. Gynäkologische Endokrinologie, 2015, 13(2):126-134.
[14] Evans MF, Frank J. Clinical practice guidelines for the diagnosis and management of osteoporosis[J]. Can Fam Physician, 1997, 43(8):635.
[15] Abdelazim IA, Faza MA, Ayash HM. Effects of Raloxifene hydrochloride on bone mineral density and serum lipids in Kuwaiti postmenopausal women with osteoporosis[J]. Arch Osteoporos, 2015, 4(1):1-5.
[16] Inzerillo AM, Zaidi M, Huang CL. Calcitonin:physiological actions and clinical applications[J]. J Pediatr Endocr Metab, 2004, 17(7):931-940.
[17] Atbinici H, Sipahio lu S, Aksoy N, et al. Effects of salmon calcitonin treatment on serum and synovial fluid bone formation and resorption markers in osteoporosis patients[J]. Acta Orthop Traumatol Turc, 2015, 49(2):160-165.
[18] 马慧萍,贾正平,葛欣,等.骨质疏松症的药物防治研究现状[J],中国药师, 2004, 7(10):816-818.
[19] Bhandari KH, Asghar W, Newa M, et al. Evaluation of bone targeting salmon calcitonin analogues in rats developing osteoporosis and adjuvant arthritis[J]. Curr Drug Deliv, 2015, 12(1):98-107.
[20] Rahnama M, Jastrzebska-Jamrogiewicz I, Jamrogiewicz R, et al. Analysis of the influence of hormone replacement therapy on osteocalcin gene expression in postmenopausal women[J]. Biomed Res Int, 2015, 2015:416929.
[21] Rossini M, Adami G, Adami S, et al. Safety issues and adverse reactions with osteoporosis management[J]. Expert Opin Drug Saf, 2016, 15(3):321-332.
[22] U.S. Preventive Services Task Force. Hormone therapy for the prevention of chronic conditions in postmenopausal women:recommendations from the U.S. Preventive Services Task Force[J]. Ann Intern Med, 2005, 142(10):855-860.
[23] Cranney A, Papaioannou A, Zytaruk N, et al. Parathyroid hormone for the treatment of osteoporosis:a systematic review[J]. CMAJ, 2006, 175(1):52-59.
[24] Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis:a review of the evidence and suggested guidelines for its use[J]. Endocr Rev, 2005, 26(5):688-703.
[爲椵湝朠??????楒?攠瑋?慮汯??椬???乳慨瑩楨潡湲慡氠?伬猠琼敩漾灥潴爠潡獬椼猯?匾漮挠楁敮瑡祬?灳物慳挠瑯楦挠慤污?捬汹椠湴楥捲慩汰?杲畡楴摩敤汥椠湴敲?潡湴?癥楮瑴愠浦楯湲???慴湥摯?扯潲湯敳?桳攠慩汮琠桭孥?嵛???愠瑏畳牴楥瑯慰獯???????????㈱??ㄠ????㈩???戲爱?嬼??崾?刲收杝椠湓獨瑩敲牡??夠???牕慥湤摡椠??????慩湭湯慴瑯愠??渠搼??????慬???￣?椠?敲瑥?慴汭??楴???味桰敯?灳潥獳椠瑷楩潴湨?潯普?獥琭牷潥湥瑫楬畹洠?牥慲湩数污慲瑡整?楤湥?瑴潨摥慲祡?獹?浦慯湲愠杯敳浴敥湯瑰?潲景?潩獳瑛敊潝瀮漠牏潳獴楥獯孰?嵲??传獉瑮整漬瀠漲爰漱猶??渲琷??日〩???‵祝????????????????扭牭?孲??嵯??攮甠湏楳整牥?偰???剳潩畳砺????即敯敺浵慭湡?????楳?敳琠?慥汲??楡???呩桤敥?敊晝昮攠捎瑡獴?潒晥?猠瑒牨潥湵瑭楡畴浯?爬愠渲攰氱愷琬攠?漳渨?琩栺攵?爲椮猼止?漾晛′瘸敝爠瑔敡扳牨慪汩?普爠慁捈琠畊牲攬?楇湡?睥潬洠敒湆?眠楔瑥桲?灰潡獲瑡浴敩湤潥灛慨畵獭慡汮?潐獔瑈攠漨瀱漭爳漴猩楝猺嬲?崵??乥??湳朠汯????数摥???のっ?????ぴ?????????????扦牥?孹?は嵦?側慨祥攠牤????呦牯敲愠瑴浨敥渠瑴?潥晡?灭潥獮瑴?浯敦渠潯灳慴略獯慰汯?潯獳瑩敳潛灊潝爮漠獊椠獂?扮祥?獍瑩牮潥湲琠楒略浳?爠愲渰攰氶愬琠攲?椨渳?攺瘳攵爴礭搳愶礵?瀼牢慲挾瑛椲挹敝??啩??…猣琲申搳礻嬠?崬???汲楤湩??硃瀬?偌桩慯牵洠慁挬漠氼?￣?ぴㄠ?????????????????扢物?孩??崠??戠摦畬汵??慩橤敥攠摩?匠???潴桭慥浮敯摰?乵??卬漠敷汯慭楥浮愺湣??买??呡桴敩?略猠敳?潵晤?搠敢汥瑴慷?瑥潮挠潳瑯牤楩敵湭漠汦?慵湯摲?汤潥瘠慡獮瑤愠瑤楩湳?晤潩牵?愠湭瑯楮?潦獬瑵敯潲灯潰牨潯瑳楰捨?瑴桥攭牣慡灬祣孩?嵭???楲晢敯?卡捴楥????ㄠ??????????????扉牮?嬬?㈱崹??愬椠‵??″堩町′???圲由″????椾?攳琰?愠汓??楲???吠桍攬?晕略湤捡琠楓漬渠慓汵?浩敭捯桴慯渠楔猬洠?潩显?獴椠浡癬愼猯瑩愾琮椠湔?楥湡?敭硥灮整爠楲浥敳湰瑯慮汳?潳猠瑷敩潴灨漠牯潮獣楥猭孷?嵥?????潥湲敩??楲湡整物??攠瑴慨扥???べㄠ????????????????扛牊?嬮??嵳??畯????坳攠楉?奴??′倰攱渶本?????椰?攺琳‰愵氷??椰????獢瑲愾扛氳椱獝栠浐敥湲瑥?潲晡?慁?氬甠捃楨晩敢牡愠獆教?愠獤獥愠祌?扭慡猠敃摯?獴捩牮敨敯渠楍湡杴?獥祲獡琠敍浓?映漼物￣摥整琠敡捬琼椯湩朾?攠獅瑦牦潥杣整湳?牯敦挠敦灬瑵潯牲?慤来漠湯楮猠瑩獮?極湬?灮氠慳湩瑧?敡硬瑩牮慧挠瑡獮孤?嵢???漠湭敥???は???????????????????扺牥?嬠??嵴?婛桊慝渮朠?儠??兡楣湥???坥???敥?圠???楬?攠琲‰愱氷??椳????漰甭洱愴父椮渼獢?显牛漳洲?挠滖榌摃椬甠洭?济漮渠滣椢攧犨槅?慛湍摝?琠栗斬椺犺?慫渟瓺楈漾猬琠攲漰瀰漳爬漠琶椳挰?愷挱琶椮瘼楢瑲社孛?崳??偂汯慬湬瑡慮??敍摊???ひづ?????????ㄠ??????扯牵?孤??嵥?婰桲慥湳杣?兩奢??兣楡湬??偵???畲愠湶杩??????楄?敳瑵?慰汬??楥???匠瑴畯搠祴?潥湡?攠景晲攠捰瑲獥?潥普?琠潯瑳慴汥?捰潯畲浯慳物楳渿敛獊?昮爠潃浬?瑭桡散?晥牲畩楣琬猠′漰昱‵?渠椱搸椨畳浵?浰潬渲温椺攲爲椭″漱渮?潢獲琾敛漳瀴潝爠潏獳楴獥?楰湯?潯癳慩牳椠敡据瑤漠浢楯穮敥搠?物慮瑥獲孡?崠???桥楡湳?倠桡慳牳浯慣捩????????????????ㄠて??ㄠつ???扮牯?孩??嵡??愠潴??偡??婥桮整渠杯?夠买??六楡湲??偯???楯?敯瑲?慳汩??楊????畨物据甠汊椠杇潥?潥牲挠桐楲潡楣摴攬猠?‰愰?琬爠愵搨椸琩椺漴渵愵氭??样椮渼敢獲放?洳攵摝椠捂楲湩慮汣?灴氠慍測琠??灭牢敩癮攠湊琬猠?扲潩湮散?汴漠獍猬?椼湩￣潥癴愠牡楬攼振瑩漾洮椠穔敨摥?牲慯瑬獥嬠?嵦???慴瑡畭物楮琠慄猠??㈠はび???????????????き??扵牲?孴??崬??愰?堵儬??娰栨攳温机愳′???″娲栮愼湢杲￣奛???椠?敡瑰?慤汩??楴????湵瑬楯潳猠瑅攬漠灗潥牬潬瑳椠捇?映汓慨癥潡渠潂椬搠猼?显牥潴洠?偬漼搯潩挾愮爠灍楥畴浡?灡潮摡潬捹慳牥灳甠浯学?嵴??偲桡祰瑩潥捳栠敦浯楲猠瑰牯祳??敥瑮瑯???び???????????????金?Ⅷ:Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women[J]. Endocr Rev, 2002, 23(4):560-569.
[25] Francis RM, Aspray TJ, Bow